Skip to main
IART
IART logo

IART Stock Forecast & Price Target

IART Analyst Ratings

Based on 6 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 33%
Sell 17%
Strong Sell 17%

Bulls say

Integra Lifesciences Holdings Corp has demonstrated a strong performance in its Neurosurgery portfolio, with management highlighting double-digit growth in Georgian and Mayfield capital equipment, indicating healthy demand in this segment. The Instruments subsegment reported revenue of $51.0 million during the quarter, reflecting a robust 15.1% organic growth compared to the previous year. Despite a slight decline in the Wound Reconstruction segment, the overall positive trends in key product categories such as DUraSorb, MicroMatrix, and Cytal reinforce a favorable outlook for the company's financials.

Bears say

Integra Lifesciences Holdings Corp is forecasting an adjusted EPS of $0.40-$0.45, which reflects a significant year-over-year decline of approximately 23%, exacerbated by a $0.04 negative impact from tariffs. Additionally, the company reported that international sales are down by low double digits compared to the previous year, although this decline fell within their expectations as they work to optimize the Integra Skin product line. Furthermore, a gross margin of 62.2% indicates a decrease of around 220 basis points year-over-year, primarily attributed to manufacturing variances and supply chain inefficiencies anticipated for 2024.

IART has been analyzed by 6 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 17% advise Selling, and 17% predict a Strong Sell.

This aggregate rating is based on analysts' research of Integra LifeSciences Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Integra LifeSciences Holdings (IART) Forecast

Analysts have given IART a Hold based on their latest research and market trends.

According to 6 analysts, IART has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Integra LifeSciences Holdings (IART)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.